Ovid Therapeutics Statistics
Total Valuation
OVID has a market cap or net worth of $441.37 million. The enterprise value is $284.32 million.
| Market Cap | 441.37M |
| Enterprise Value | 284.32M |
Important Dates
The next estimated earnings date is Wednesday, November 11, 2026, before market open.
| Earnings Date | Nov 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
OVID has 195.30 million shares outstanding. The number of shares has increased by 71.09% in one year.
| Current Share Class | 195.30M |
| Shares Outstanding | 195.30M |
| Shares Change (YoY) | +71.09% |
| Shares Change (QoQ) | +45.00% |
| Owned by Insiders (%) | 2.18% |
| Owned by Institutions (%) | 71.03% |
| Float | 163.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 278.82 |
| Forward PS | 2,747.59 |
| PB Ratio | 1.99 |
| P/TBV Ratio | 2.10 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 179.61 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.39, with a Debt / Equity ratio of 0.06.
| Current Ratio | 12.39 |
| Quick Ratio | 11.75 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -25.96% and return on invested capital (ROIC) is -72.03%.
| Return on Equity (ROE) | -25.96% |
| Return on Assets (ROA) | -23.46% |
| Return on Invested Capital (ROIC) | -72.03% |
| Return on Capital Employed (ROCE) | -26.15% |
| Weighted Average Cost of Capital (WACC) | 5.36% |
| Revenue Per Employee | $68,826 |
| Profits Per Employee | -$1.50M |
| Employee Count | 23 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +29.14% in the last 52 weeks. The beta is 0.23, so OVID's price volatility has been lower than the market average.
| Beta (5Y) | 0.23 |
| 52-Week Price Change | +29.14% |
| 50-Day Moving Average | 2.63 |
| 200-Day Moving Average | 2.33 |
| Relative Strength Index (RSI) | 38.03 |
| Average Volume (20 Days) | 1,805,860 |
Short Selling Information
The latest short interest is 18.95 million, so 9.70% of the outstanding shares have been sold short.
| Short Interest | 18.95M |
| Short Previous Month | 21.15M |
| Short % of Shares Out | 9.70% |
| Short % of Float | 11.60% |
| Short Ratio (days to cover) | 11.15 |
Income Statement
In the last 12 months, OVID had revenue of $1.58 million and -$34.48 million in losses. Loss per share was -$0.28.
| Revenue | 1.58M |
| Gross Profit | 1.58M |
| Operating Income | -58.06M |
| Pretax Income | -34.49M |
| Net Income | -34.48M |
| EBITDA | -57.97M |
| EBIT | -58.06M |
| Loss Per Share | -$0.28 |
Balance Sheet
The company has $117.22 million in cash and $12.72 million in debt, with a net cash position of $157.05 million or $0.80 per share.
| Cash & Cash Equivalents | 117.22M |
| Total Debt | 12.72M |
| Net Cash | 157.05M |
| Net Cash Per Share | $0.80 |
| Equity (Book Value) | 209.89M |
| Book Value Per Share | 1.14 |
| Working Capital | 113.64M |
Cash Flow
| Operating Cash Flow | -54.77M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 84,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -54.77M |
| FCF Per Share | -$0.28 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -3,667.59% |
| Pretax Margin | -2,178.84% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OVID does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -71.09% |
| Shareholder Yield | -71.09% |
| Earnings Yield | -7.81% |
| FCF Yield | -12.41% |
Analyst Forecast
The average price target for OVID is $6.11, which is 170.35% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.11 |
| Price Target Difference | 170.35% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | -68.10% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
OVID has an Altman Z-Score of 3.45 and a Piotroski F-Score of 1.
| Altman Z-Score | 3.45 |
| Piotroski F-Score | 1 |